News

The Muscular Dystrophy Association’s 18th Annual Muscle Team Gala & Benefit Auction will take place this Tuesday, January 6 and will include athletes from Metro-New York area sports teams such as the New York Giants, New York Jets, and New York Red Bulls, plus representatives from the New York Aqueduct Racetrack, Muscle Team…

Researchers at the Ohio State University Wexner Medical Center, along with experts at several other medical facilities, have found that Duchenne muscular dystrophy (DMD)-related declines in heart functioning may be slowed by already existing heart medications. The research appeared in the online version of The Lancet Neurology. DMD is characterized by…

Patients suffering from muscular dystrophy may soon be able to independently monitor their therapeutic response to medications with a revolutionary smartphone-linked device. The Acoustical Society of America invited the creators and researchers behind this device to their annual meeting last October 30, 2014 to give a…

South Plainfield, NJ-based biopharmaceutical company PTC Therapeutics, Inc. recently announced that it has launched a rolling submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for pipeline nonsense mutation Duchenne muscular dystrophy (nmDMD) treatment Translarna™. This process enables…

Stuart W. Peltz, Ph.D, the CEO of biopharmaceutical company PTC Therapeutics, Inc., was recently granted the 2014 Legend of Technology Award for Vision, Innovation, and Leadership, in recognition of the impact of his work in the field of technological industry based largely on PTC’s investigational therapy for DMD. The…

A trio of companies, comprised of CITGO Marketer Flash Market Inc., Core Mark and CITGO Petroleum Corporation recently hosted the 10th Annual Passport to a Cure benefit in Little Rock, Arkansas for the local chapter of the Muscular Dystrophy Association (MDA), the world’s leading non-profit organization for muscle disease, including muscular…

PTC Therapeutics, Inc., a biopharmaceutical company with a focus on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes, has just announced one of its leading pipeline products, Translarna™ (ataluren), has received orphan-drug designation from the US Food and Drug Administration and European Medicines…

The “Solid Suit” is actually designed to be soft, like the one pictured above, and could be worn by people with DMD under their clothes. Hackensack, N.J. based nonprofit Parent Project Muscular Dystrophy (PPMD), which is dedicated to fighting and eventually prevailing over Duchenne muscular dystrophy…

According to a new research study by scientists at the Stanford University School of Medicine in mouse modeling of Duchenne muscular dystrophy, faulty connective-tissue genes associated with symptoms like fibrosis and muscle weakness are expressed in muscle stem cells of afflicted subjects. As with human patients, mice with…

Carlsbad, California-based Isis Pharmaceuticals, Inc. recently announced the launch of a study for ISIS-DMPKRx, indicated to treat Myotonic Dystrophy Type 1 (DM1), a rare neuromuscular disease caused by an abnormal and toxic production of dystrophia myotonica-protein kinase (DMPK) RNA in cells, which is an abnormally long strand of RNA, that accumulates in cell…